Director's Commitments

Hikma Pharmaceuticals Plc
06 December 2006


                Update on Non-Executive Director's Appointments

LONDON, 6 December 2006 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK), the
multinational pharmaceuticals group, announces that Michael Ashton, a
non-executive Director and Chairman of the Remuneration Committee, has been
appointed as the Chief Executive Officer of LMA International NV, a Singapore
listed company.

                                    - ENDS -
Enquiries:

Hikma Pharmaceuticals PLC
Susan Ringdal                                     [phone]
Investor Relations Director

Brunswick Group
Jon Coles / Justine McIlroy / Alex Tweed          [phone]

About Hikma
Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the United States,
the Middle East and North Africa ('MENA') region and Europe. In 2005, the Group
had revenue of $262 million and profit attributable to shareholders of $44
million. At 31 December 2005, the Group had over 1,800 employees. For news and
other information, please visit www.hikma.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange